These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 39348980)

  • 1. Characterization of Molecular Subtypes of Rat Mammary Cancer and Their Association With Environmental Exposures.
    Nishimura Y; Iizuka D; Takabatake M; Daino K; Nishimura M; Morioka T; Shimada Y; Kakinuma S; Imaoka T
    Anticancer Res; 2024 Oct; 44(10):4261-4272. PubMed ID: 39348980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.
    Bastien RR; Rodríguez-Lescure Á; Ebbert MT; Prat A; Munárriz B; Rowe L; Miller P; Ruiz-Borrego M; Anderson D; Lyons B; Álvarez I; Dowell T; Wall D; Seguí MÁ; Barley L; Boucher KM; Alba E; Pappas L; Davis CA; Aranda I; Fauron C; Stijleman IJ; Palacios J; Antón A; Carrasco E; Caballero R; Ellis MJ; Nielsen TO; Perou CM; Astill M; Bernard PS; Martín M
    BMC Med Genomics; 2012 Oct; 5():44. PubMed ID: 23035882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
    Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
    BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative analysis of the molecular subtype landscape in canine and human mammary gland tumors.
    Bergholtz H; Lien T; Lingaas F; Sørlie T
    J Mammary Gland Biol Neoplasia; 2022 Jun; 27(2):171-183. PubMed ID: 35932380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human basal-like breast cancer is represented by one of the two mammary tumor subtypes in dogs.
    Watson J; Wang T; Ho KL; Feng Y; Mahawan T; Dobbin KK; Zhao S
    Breast Cancer Res; 2023 Oct; 25(1):114. PubMed ID: 37789381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolactin-induced mouse mammary carcinomas model estrogen resistant luminal breast cancer.
    Arendt LM; Rugowski DE; Grafwallner-Huseth TA; Garcia-Barchino MJ; Rui H; Schuler LA
    Breast Cancer Res; 2011 Jan; 13(1):R11. PubMed ID: 21276249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subtyping of male breast cancer by PAM50 and immunohistochemistry: a pilot study of a consecutive Danish cohort.
    Christensen LG; Lautrup MD; Lyng MB; Möller S; Jylling AMB
    APMIS; 2020 Sep; 128(9):523-530. PubMed ID: 32579768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression and methylation patterns partition luminal-A breast tumors into distinct prognostic subgroups.
    Netanely D; Avraham A; Ben-Baruch A; Evron E; Shamir R
    Breast Cancer Res; 2016 Jul; 18(1):74. PubMed ID: 27386846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A deep learning image-based intrinsic molecular subtype classifier of breast tumors reveals tumor heterogeneity that may affect survival.
    Jaber MI; Song B; Taylor C; Vaske CJ; Benz SC; Rabizadeh S; Soon-Shiong P; Szeto CW
    Breast Cancer Res; 2020 Jan; 22(1):12. PubMed ID: 31992350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome.
    Aure MR; Vitelli V; Jernström S; Kumar S; Krohn M; Due EU; Haukaas TH; Leivonen SK; Vollan HK; Lüders T; Rødland E; Vaske CJ; Zhao W; Møller EK; Nord S; Giskeødegård GF; Bathen TF; Caldas C; Tramm T; Alsner J; Overgaard J; Geisler J; Bukholm IR; Naume B; Schlichting E; Sauer T; Mills GB; Kåresen R; Mælandsmo GM; Lingjærde OC; Frigessi A; Kristensen VN; Børresen-Dale AL; Sahlberg KK;
    Breast Cancer Res; 2017 Mar; 19(1):44. PubMed ID: 28356166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intrinsic subtypes from PAM50 gene expression assay in a population-based breast cancer cohort: differences by age, race, and tumor characteristics.
    Sweeney C; Bernard PS; Factor RE; Kwan ML; Habel LA; Quesenberry CP; Shakespear K; Weltzien EK; Stijleman IJ; Davis CA; Ebbert MT; Castillo A; Kushi LH; Caan BJ
    Cancer Epidemiol Biomarkers Prev; 2014 May; 23(5):714-24. PubMed ID: 24521995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes.
    Prat A; Karginova O; Parker JS; Fan C; He X; Bixby L; Harrell JC; Roman E; Adamo B; Troester M; Perou CM
    Breast Cancer Res Treat; 2013 Nov; 142(2):237-55. PubMed ID: 24162158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transgenic IGF-IR overexpression induces mammary tumors with basal-like characteristics, whereas IGF-IR-independent mammary tumors express a claudin-low gene signature.
    Franks SE; Campbell CI; Barnett EF; Siwicky MD; Livingstone J; Cory S; Moorehead RA
    Oncogene; 2012 Jul; 31(27):3298-309. PubMed ID: 22020329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer.
    Wang S; Liu JC; Kim D; Datti A; Zacksenhaus E
    Breast Cancer Res; 2016 Jan; 18(1):9. PubMed ID: 26781438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics.
    Jönsson G; Staaf J; Vallon-Christersson J; Ringnér M; Holm K; Hegardt C; Gunnarsson H; Fagerholm R; Strand C; Agnarsson BA; Kilpivaara O; Luts L; Heikkilä P; Aittomäki K; Blomqvist C; Loman N; Malmström P; Olsson H; Johannsson OT; Arason A; Nevanlinna H; Barkardottir RB; Borg A
    Breast Cancer Res; 2010; 12(3):R42. PubMed ID: 20576095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Male breast cancer: correlation between immunohistochemical subtyping and PAM50 intrinsic subtypes, and the subsequent clinical outcomes.
    Sánchez-Muñoz A; Vicioso L; Santonja A; Álvarez M; Plata-Fernández Y; Miramón J; Zarcos I; Ramírez-Tortosa CL; Montes-Torres J; Jerez JM; de Luque V; Llácer C; Fernández-De Sousa CE; Pérez-Villa L; Alba E
    Mod Pathol; 2018 Feb; 31(2):299-306. PubMed ID: 28984296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triple-negative vimentin-positive heterogeneous feline mammary carcinomas as a potential comparative model for breast cancer.
    Caliari D; Zappulli V; Rasotto R; Cardazzo B; Frassineti F; Goldschmidt MH; Castagnaro M
    BMC Vet Res; 2014 Sep; 10():185. PubMed ID: 25249140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53R172H and p53R245W Hotspot Mutations Drive Distinct Transcriptomes in Mouse Mammary Tumors Through a Convergent Transcriptional Mediator.
    McDaniel JM; Morrissey RL; Dibra D; Patel LR; Xiong S; Zhang Y; Chau GP; Su X; Qi Y; El-Naggar AK; Lozano G
    Cancer Res Commun; 2024 Aug; 4(8):1991-2007. PubMed ID: 38994678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PAM50- and immunohistochemistry-based subtypes of breast cancer and their relationship with breast cancer mortality in a population-based study.
    Wang L; Li Q; Aushev VN; Neugut AI; Santella RM; Teitelbaum S; Chen J
    Breast Cancer; 2021 Nov; 28(6):1235-1242. PubMed ID: 34003448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between breast cancer subtypes determined by immunohistochemistry and n-COUNTER PAM50 assay: a real-world study.
    Lopez-Tarruella S; Del Monte-Millán M; Roche-Molina M; Jerez Y; Echavarria Diaz-Guardamino I; Herrero López B; Gamez Casado S; Marquez-Rodas I; Alvarez E; Cebollero M; Massarrah T; Ocaña I; Arias A; García-Sáenz JÁ; Moreno Anton F; Olier Garate C; Moreno Muñoz D; Marrupe D; Lara Álvarez MÁ; Enrech S; Bueno Muiño C; Martín M
    Breast Cancer Res Treat; 2024 Jan; 203(1):163-172. PubMed ID: 37773555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.